Cancer in the immunosuppressed patient.
D000361:Agammaglobulinemia / Q000139:chemically induced; D000818:Animals; D000961:Antilymphocyte Serum / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002277:Carcinoma / Q000139:chemically induced; D002280:Basal Cell Carcinoma / Q000139:chemically induced; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000139:chemically induced; D006801:Humans; D007108:Immune Tolerance; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007890:Leiomyosarcoma; D007938:Leukemia / Q000139:chemically induced; D008048:Lip Neoplasms / Q000139:chemically induced; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced; D051379:Mice; D009369:Neoplasms / Q000139:chemically induced*; D011565:Psoriasis / Q000188:drug therapy; D012514:Sarcoma, Kaposi / Q000139:chemically induced; D012878:Skin Neoplasms / Q000139:chemically induced; D014181:Transplantation Immunology; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents